Carolyn F. Deacon
Carolyn F. Deacon

Associate Professor


  1. Published

    GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

    Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In : American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

    Research output: Contribution to journalJournal article

  2. Published

    Therapeutic strategies based on glucagon-like peptide 1.

    Deacon, Carolyn F., 2004, In : Diabetes. 53, 9, p. 2181-9 8 p.

    Research output: Contribution to journalJournal article

  3. Published

    GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

    Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In : American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

    Research output: Contribution to journalJournal article

  4. Published

    Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

    Deacon, Carolyn F., 2008, In : Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.

    Research output: Contribution to journalJournal article

  5. Published

    Potential of liraglutide in the treatment of patients with type 2 diabetes

    Deacon, Carolyn F., 2009, In : Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

    Research output: Contribution to journalJournal article

  6. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In : Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journalJournal article

  7. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In : Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journalJournal article

  8. Published

    MK-431 (Merck).

    Deacon, Carolyn F., 2005, In : Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

    Research output: Contribution to journalJournal article

  9. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In : Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journalJournal article

  10. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In : Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

    Research output: Contribution to journalJournal article

Previous 12 3 4 5 6 7 8 9 ...22 Next

ID: 9220